Evercore ISI maintained an Outperform on Inspire Medical Systems, Inc. (INSP) on February 27, 2026, citing that 3 of the 6 new HCPCS codes announced by CMS are relevant for the company. The INSP analyst rating note highlights coding clarity for hypoglossal nerve stimulation devices and keeps Evercore’s constructive stance. Investors should note the stock moved 5.59% ($3.6) since the report and that price detail at note time was not provided.
INSP analyst rating: Evercore ISI maintains Outperform
Evercore ISI kept an Outperform rating for INSP on February 27, 2026, and emphasized coding relevance for Inspire’s devices. The firm framed the CMS decision as supportive for procedure adoption and reimbursement clarity, which underpins their positive view.
What Evercore said about CMS codes and clinical relevance
Evercore ISI noted that 3 of the 6 codes are relevant for Inspire, improving billing alignment for hypoglossal nerve stimulation. This clarity can reduce administrative friction for hospitals and sleep centers. The analyst argued clearer codes may ease uptake and support procedure growth, which can translate to steadier revenue expansion for Inspire Medical Systems, Inc.
Market reaction and INSP stock performance
Shares reacted positively, with a 5.59% ($3.6) move reported since the note was published. That move shows the market views coding clarity as incremental good news for procedure volumes. Market cap stands at $1,872,687,171, which frames how material any change in reimbursement or adoption will be for shareholder value.
Price targets, rating implications, and investor action
Evercore ISI maintained the rating but did not publish a new price target in the note cited by StreetInsider. A maintained Outperform means analysts expect above-market returns versus peers, not a change in fundamentals. For investors, the rating signals continued conviction. Active investors may re-evaluate position sizing while longer-term holders should watch procedure volume trends and reimbursement updates.
Historical analyst coverage and context for the INSP analyst rating
Analyst coverage of Inspire has focused on procedural adoption, reimbursement, and surgical throughput. Evercore’s note fits that pattern by tying CMS coding to adoption potential. Past ratings moves have tracked clinical publications and CMS actions, so investors should monitor both regulatory and trial updates as drivers of future ratings.
Meyka AI grade and what it means for investors
Meyka AI rates INSP with a grade of A. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Use the Meyka AI grade together with Evercore’s maintained Outperform when forming allocations. For real-time updates visit our INSP page at Meyka INSP page.
Final Thoughts
Evercore ISI’s February 27, 2026 note kept an Outperform on Inspire Medical Systems, Inc. (INSP) and pointed out that 3 of the 6 new CMS HCPCS codes are relevant for the company. That maintained INSP analyst rating reflects comfort with near-term reimbursement clarity and its likely positive effect on procedure adoption. The market reacted with a 5.59% ($3.6) move, showing investors view the coding update as supportive. Meyka AI rates INSP with a grade of A based on benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Investors should treat the maintained rating as continued analyst confidence, not a guarantee, and watch procedure volumes, CMS guidance, and any updated price targets from other firms. For portfolio decisions, balance this analyst view with company fundamentals and risk tolerance, and consult your advisor if needed.
FAQs
What did Evercore ISI do in the February 27, 2026 note for INSP?
Evercore ISI maintained an Outperform on Inspire Medical Systems on February 27, 2026 and highlighted that 3 of the 6 new CMS HCPCS codes are relevant for INSP analyst rating and future reimbursement clarity.
How did the market react to the INSP analyst rating update?
The stock moved 5.59% ($3.6) after the note, reflecting investor approval of coding clarity and the maintained INSP analyst rating as supportive for procedure adoption and revenue.
Does the Evercore note include a new price target for INSP?
The cited Evercore note did not publish a new INSP price target. The firm maintained Outperform but did not change the publicly referenced price target in the StreetInsider summary.
What does Meyka AI’s grade mean for INSP investors?
Meyka AI rates INSP with a grade of A, based on S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. This complements the INSP analyst rating but is not financial advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
